依达拉奉治疗急性脑梗死的临床研究

Clinical Observation of Edaravone in Treatment of Acute Cerebral Infarction

目的:评价依达拉奉治疗发病72h内脑梗死的疗效。方法:100例72h内发病的急性脑梗死患者随机分成两组,两组均用葛根素注射液0.4g加入生理盐水中静脉滴注,治疗组在此基础上再加用依达拉奉30mg加入生理盐水100mL静脉滴注,每日两次,14d为1疗程。评价治疗前后神经功能缺失评分和日常生活能力的变化及疗效,监测用药前后肝肾功能的变化。结果:治疗组14d后神经功能显著改善,与对照组相比差异有显著性(P=0.004),至21d差异更显著(P=0.003),治疗组有效率(76.00%)明显高于对照组(58.00%);治疗组治疗14d的日常生活能力明显改善,与对照组相比差异有显著性(P<0.05),至60d差异更显著,治疗组有效率(70.00%)明显高于对照组(54.00%),两组患者治疗前后肝肾功能指标无明显改变。结论:依达拉奉治疗急性脑梗死是安全有效的。

Objective To observe the clinical efficacy and safety of edaravone in treating acute cerebral infarction. Methods 100 cases with acute cerebral infarction enrolled within 72h of onset were randomized to receive intravenous injection of either edaravone （30 mg in 250 mL of normal saline, bid） plus puerarin injection （0.4 g,qd） or contrast therapy （puerarin injection 0.4 g intravenous injection qd） in a 14-day cycle of the therapy. The efficasy was assessed using the neurological functional deficit scores by European Stroke Scale （ESS） and activities of daily living （ADL）. The safety of edaravone was assessed by comparision of the hepatic and renal fuction before and after the therepy. Results The ESS score was improved significally in edaravone group than that in contrast group after 14 days （P = 0.004） and 21 days （P = 0.003）. The ADL was improved significally in edaravone group than that in control group after 14 days （P 〈 0.05） and 60 days. Conclusion Edaravone is safe and effective in the treatment of acute cerebral infarction.